Drug Profile
MK 1075
Alternative Names: MK1075Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Hepatitis-C in Moldova (PO, Tablet)
- 28 May 2018 No recent reports of development identified for phase-I development in Hepatitis-C in Belgium (PO, Tablet)
- 01 Dec 2015 Merck Sharp and Dohme completes a phase I trial for Hepatitis C (genotype 1 and genotype 2) in Belgium and Moldova (NCT02461563)